Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection
17 juil. 2023 08h45 HE
|
Novan, Inc.
– The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan’s assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15...
Novan to Report First Quarter 2023 Financial Results on May 15, 2023
08 mai 2023 09h05 HE
|
Novan, Inc.
DURHAM, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2023 financial results on Monday, May...
Novan Announces Publication of Psoriasis Patient Data Demonstrating Need for Rapid Symptom Improvement¹
27 avr. 2023 09h10 HE
|
Novan, Inc.
Published results from a National Psoriasis Foundation-fielded survey included responses from more than 400 patients across US1 Findings highlight impact on patient adherence of early onset of...
Novan Moves Forward with Unified Corporate Branding
08 mars 2023 09h00 HE
|
Novan, Inc.
– Novan is a fully integrated pharmaceutical company with proven capabilities across drug development through to commercialization – – EPI Health adopts Novan corporate branding, creating unified...
EPI Health, a Novan Company, Enters into Exclusive License Agreement with Sato Pharmaceutical Co., Ltd. for RHOFADE® in Japan
21 déc. 2022 08h00 HE
|
Novan, Inc.
DURHAM, N.C., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that EPI Health, LLC, a fully consolidated subsidiary of Novan, has entered...
EPI Health, a Novan Company, Executes a $15.0 Million Financing Agreement
02 déc. 2022 08h00 HE
|
Novan, Inc.
– Agreement provides immediate access to cash flow – – EPI Health leveraging accounts receivables from commercial product sales to bolster working capital needs – DURHAM, N.C., Dec. 02, 2022 ...
Novan Reports Third Quarter 2022 Financial Results and Provides Corporate Update
14 nov. 2022 07h00 HE
|
Novan, Inc.
– Rhofade prescriptions increased 37% for third quarter year-to-date from prior year – – Continued progress toward submission of berdazimer gel, 10.3% (SB206) New Drug Application (NDA), targeted...
Novan to Report Third Quarter 2022 Financial Results on November 14, 2022
07 nov. 2022 09h00 HE
|
Novan, Inc.
DURHAM, N.C., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its third quarter 2022 financial results on Monday,...
EPI Health, a Novan Company, and MC2 Therapeutics Present New Data In Multiple Posters Highlighting WYNZORA’s® Unique PAD Technology™ at the 42nd Annual Fall Clinical Dermatology Conference®
21 oct. 2022 08h35 HE
|
Novan, Inc.
DURHAM, N.C. and COPENHAGEN, Denmark, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), EPI Health, a Novan Company, and MC2 Therapeutics today announced...
EPI Health, a Novan Company, and MC2 Therapeutics Announce Data from Survey Conducted by National Psoriasis Foundation Presented at 42nd Annual Fall Clinical Dermatology Conference®
21 oct. 2022 08h35 HE
|
Novan, Inc.
DURHAM, N.C. and COPENHAGEN, Denmark, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), EPI Health, a Novan Company, and MC2 Therapeutics today announced that...